Daniel D Karp
Overview
Explore the profile of Daniel D Karp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
3992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lema C, Cheng K, Anderson D, Miller C, Karp D, McPherson D, et al.
J Clin Transl Sci
. 2024 Feb;
8(1):e33.
PMID: 38384924
Translation is the process of turning observations in the research laboratory, clinic, and community into interventions that improve people's health. The Clinical and Translational Science Awards (CTSA) program is a...
12.
Piha-Paul S, Xu B, Dumbrava E, Fu S, Karp D, Meric-Bernstam F, et al.
Oncologist
. 2024 Feb;
29(4):e514-e525.
PMID: 38297981
Purpose: This first-in-human phase I dose-escalation study evaluated the safety, pharmacokinetics, and efficacy of tinengotinib (TT-00420), a multi-kinase inhibitor targeting fibroblast growth factor receptors 1-3 (FGFRs 1-3), Janus kinase 1/2,...
13.
DiPeri T, Kong K, Varadarajan K, Karp D, Ajani J, Pant S, et al.
Mol Cancer Ther
. 2023 Jun;
22(8):976-984.
PMID: 37339271
We sought to assess discordance of HER2 status in patients with HER2-amplified/expressing solid tumors who underwent reevaluation of HER2 status. Patients with metastatic solid tumors and HER2 expression by IHC...
14.
Piha-Paul S, Tseng C, Tran H, Gao M, Karp D, Subbiah V, et al.
Cancer Chemother Pharmacol
. 2023 Jun;
92(2):107-118.
PMID: 37314501
Purpose: Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical successes, but drug resistance often develops due to aberrant...
15.
Nelson B, Tsimberidou A, Fu X, Fu S, Subbiah V, Sood A, et al.
Oncologist
. 2023 Jun;
28(12):1100-e1292.
PMID: 37311055
Background: Preclinical models suggest synergy between anti-angiogenesis therapy, mammalian target of rapamycin (mTOR), and histone deacetylase inhibitors to promote anticancer activity. Methods: This phase I study enrolled 47 patients between...
16.
Altan M, Tu J, Milton D, Yilmaz B, Tian Y, Fossella F, et al.
Cancer
. 2023 May;
129(17):2685-2693.
PMID: 37129197
Background: In lung cancer, overexpression of nuclear export proteins can result in inactivation of critical tumor suppressor proteins and cell-cycle regulators. Selective suppression of nuclear export proteins has immunomodulatory activities....
17.
Carmagnani Pestana R, Moyers J, Roszik J, Sen S, Hong D, Naing A, et al.
Clin Cancer Res
. 2023 Apr;
29(9):1708-1718.
PMID: 37058010
Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in...
18.
Nelson B, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore J, et al.
Cancer
. 2023 Apr;
129(14):2201-2213.
PMID: 37016732
Background: Selinexor (KPT-330) is a potent inhibitor of exportin 1 (XPO1), in turn inhibiting tumor growth. Selinexor enhances the antitumor efficacy of eribulin in triple-negative breast cancer (TNBC) in vitro...
19.
Son J, Lin H, Fu S, Biter A, Dumbrava E, Karp D, et al.
J Immunother Precis Oncol
. 2023 Feb;
6(1):10-18.
PMID: 36751659
Introduction: We aimed to identify clinical, pathologic, and treatment factors that are predictive of response and survival in patients with cervical cancer referred to phase I clinical trials. Methods: Patients...
20.
Dagher H, Chaftari A, Subbiah I, Malek A, Jiang Y, Lamie P, et al.
Elife
. 2023 Feb;
12.
PMID: 36748905
Background: An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease in non-cancer patients. The long-term consequences of COVID-19 are not fully...